Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study

Title
Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study
Author(s)
장병익진윤태[진윤태]이강문[이강문]조주연[조주연]이창균[이창균]박동일[박동일]김지원[김지원]구자설[구자설]임종필[임종필]박수정[박수정]
Keywords
INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; SONGPA-KANGDONG DISTRICT; CROHNS-DISEASE; POPULATION; REMISSION; CONSENSUS; OUTCOMES; SEOUL
Issue Date
201312
Publisher
WILEY-BLACKWELL
Citation
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, v.28, no.12, pp.1829 - 1833
Abstract
Background/AimsInfliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety of infliximab in Korean patients with UC were assessed. MethodsThis was a retrospective multicenter study including all adult patients who received at least one infliximab infusion for UC. Short- and long-term clinical outcomes and adverse events of infliximab therapy were evaluated, and predictors of response were identified. ResultsA total of 134 UC patients were included. The indications for infliximab therapy were acute severe UC in 28%, steroid-dependency in 38%, and steroid-refractoriness in 33%, respectively. The rates of clinical response and remission were 87% and 45% at week 8. In multivariate analysis, we found significant predictors of clinical remission at week 8: immunomodulator-naive (odds ratio [OR]=4.89, 95% confidence interval [CI]: 1.44-16.66, P=0.01), hemoglobin11.5g/dL (OR=4.47, 95% CI: 1.48-13.45, P=0.008), C-reactive protein3mg/dL (OR=4.77, 95% CI: 1.43-15.94, P=0.01), and response at week 2 (OR=20.54, 95% CI: 2.40-175.71, P=0.006). Long-term clinical response and remission rates were 71% and 52%, respectively, and mucosal healing was the only factor influencing long-term response. Adverse events related to infliximab occurred in 15% of patients, and most of them were mild and transient. ConclusionsInfliximab is effective and safe in the treatment of active UC in Korea. No history of previous immunomodulator use and high baseline C-reactive protein are independent predictors of good response.
URI
http://hdl.handle.net/YU.REPOSITORY/28235http://dx.doi.org/10.1111/jgh.12324
ISSN
0815-9319
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE